trending Market Intelligence /marketintelligence/en/news-insights/trending/B89JwhjQTrJyPsHI9D1TCw2 content esgSubNav
In This List

Sundrug fiscal Q3 profit climbs 12.8% YOY

Blog

Using ESG Analysis to Support a Sustainable Future

Video

S&P Capital IQ Pro | Powered by Expert Insights

Blog

Q&A: Streamlining Analytics for TCFD Reporting

Blog

Evergrande and the wider impact: a sentiment analytics based perspective


Sundrug fiscal Q3 profit climbs 12.8% YOY

Sundrug Co. Ltd. said its normalized net income for the fiscal third quarter ended Dec. 31, 2014, was ¥42.41 per share, a gain of 17.6% from ¥36.05 per share in the year-earlier period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥5.13 billion, an increase of 12.8% from ¥4.54 billion in the year-earlier period.

The normalized profit margin climbed to 4.2% from 4.0% in the year-earlier period.

Total revenue increased 6.2% year over year to ¥120.70 billion from ¥113.66 billion, and total operating expenses climbed 5.7% from the prior-year period to ¥112.68 billion from ¥106.56 billion.

Reported net income rose 16.8% on an annual basis to ¥5.09 billion, or ¥42.13 per share, from ¥4.36 billion, or ¥34.59 per share.

As of Feb. 13, US$1 was equivalent to ¥118.68.